Insulin drug maker Novo Nordisk shares slide Add to ...

SHARE

Replay
Reuters |
Show Description
Shares in Danish drug maker Novo Nordisk fell by as much as 15%, after it was hit hard by U.S. regulators' demands for further clinical testing of its new long-acting insulin drug Tresiba. Joanna Partridge reports

Articles Related to this Story

More from this section

Most Popular

Editor's Picks

Globe Shows »

Careers
Put your best foot forward with our expert advice